Boyden is pleased to share the appointment news of Dr. Eric Campeau, a recruitment co-led by Chantal Hevey and Roger T. Duguay
Laval, QC - November 29, 2021
LQT Therapeutics, Inc. is excited to welcome Eric Campeau as Vice President – Translational Research. Eric has spent nearly 30 years in biomedical research, most recently as Vice President of Translational Biology at Zenith Epigenetics, Ltd. He has been involved in the preclinical and clinical development of ZEN-3694 since the beginning of Zenith in 2013. Most notably, the Translational Medicine team, led by Dr. Campeau, made key contributions in the design of a patient pre-selection approach for a randomized metastatic castration resistant prostate cancer study.
Prior to Zenith, Dr. Campeau was a Scientist at Resverlogix Corp., an instructor at the University of Massachusetts Medical School, and a Scientist at the Lawrence Berkeley National Laboratory. Dr. Campeau obtained his Ph.D. in Human Genetics at McGill University.
“Eric’s knowledge and experience is a perfect fit for LQTT as we aggressively advance our platform to include oncology,” said Debra Odink, Chief Development Officer and Senior VP of Technical Operations at LQT Therapeutics. “Eric will be collaborating with Dr. Donald McDonnell and his research team at Duke University School of Medicine to evaluate SGK1 inhibitors as potential treatments for patients with breast and prostate cancer.”
SGK1 is increasingly shown to be mutated or overexpressed in different cancers as well as to be involved in the resistance to existing therapies. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. Our aim will be to identify which patients could benefit from a treatment involving SGK1 inhibitors using precision medicine tools that have become recently available.
About LQT Therapeutics, Inc.
LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. Launched in 2019 by the Fonds de Solidarité FTQ. LQT Therapeutics, Inc. was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development. For more information, please visit www.lqttrx.com
Original Source: LQT Therapeutics News
